Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis
From the Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
Address correspondence to Dr T.B. Niewold, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St, New York, NY 10021, email: niewoldt{at}hss.edu. Address reprint requests to Dr M.J. Harrison, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St, New York, NY 10021
 |
Abstract |
|---|
Rheumatoid arthritis is both common and chronic, with significant consequences for multiple organ systems. Better understanding of its pathophysiology has led to the development of targeted therapies that have dramatically improved outcomes. The key to therapeutic success lies in identifying individuals who will have severe destructive disease as early as possible, so that effective treatment can be initiated before irreversible damage occurs. Anti-cyclic citrullinated peptide (anti-CCP) antibody testing is particularly useful in the diagnosis of rheumatoid arthritis, with high specificity, presence early in the disease process, and ability to identify patients who are likely to have severe disease and irreversible damage. However, its sensitivity is low, and a negative result does not exclude disease. Anti-CCP antibodies have not been found at a significant frequency in other diseases to date, and are more specific than rheumatoid factor for detecting rheumatoid arthritis. We discuss anti-CCP antibody testing in rheumatoid arthritis, with an emphasis on diagnostic performance, prognostic capability, and relevance to pathogenesis and new treatment paradigms in rheumatoid arthritis.